KO Research Update — July 17, 2026
Updated Thesis
The Coca-Cola Company is a leading global beverage company specializing in non-alcoholic drinks with a durable competitive moat driven by its strong brand and extensive distribution network. The business quality is high, evidenced by a 43.6% return on equity, robust gross margin of 61.7%, and solid revenue and earnings growth of 12.1% and 17.8% respectively in the most recent quarter. Despite these strengths, the stock is currently overvalued, trading at a price-to-sales ratio of 7.41 and a trailing P/E of 26.62, which is expensive relative to its five-year history.
The investment grade as of this refresh is C — average business quality. High-tier business, expensive valuation with 10.2% downside to $76.30 fair value
Key Metrics at a Glance
- Revenue growth: +12.1% year over year
- Net margin: 27.8%
- Forward P/E: 26.6x
- Fair value upside: -10.2% to our estimate of $76
Current price: $84.92
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Coca-Cola Company remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full KO research →](/stocks/KO)